Methylated Biomarkers Predictive of Endometrial Cancer Risk

The goal of this observational study is to identify endometrial cancer risk predictive biomarkers and to optimise the methodology for their detection and quantification in non-invasive samples.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Key information

Conditions

Endometrial Cancer Endometrial Neoplasms Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Genital Diseases Genital Diseases, Female Genital Neoplasms, Female Neoplasms Neoplasms by Site Urogenital Diseases Urogenital Neoplasms Uterine Diseases Uterine Neoplasms

Age range

45 year–70 year

Sex eligibility

Female

Study type

Observational

Primary location

Manchester University NHS Foundation Trust

Manchester, M13 9WL, United Kingdom

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Women aged 45-70 years
Attending St Mary's Hospital, Manchester for an elective hysterectomy by any route for either the treatment of endometrial cancer or a benign gynaecological condition
Able to consent to participation in the study

Exclusion criteria

Presence of malignancy asides from endometrial cancer
Undergoing elective hysterectomy for suspected ovarian cancer

Treatment and study plan

Hysterectomy

Procedure

Elective hysterectomy

Primary outcomes

Sensitivity, specificity, negative and positive predictive value of single gene methylation classifiers in predicting the presence of endometrial cancer in minimally- and invasive samples

Time frame: 1 day

Secondary outcomes

Sensitivity, specificity, positive and negative predictive value of a multi-gene methylation classifier for predicting the presence of endometrial cancer

Time frame: 1 day

Sponsors and collaborators

Lead sponsor

University of Manchester

Other

Collaborators

Queen Mary University of London

Registry information

Acronym: BioMEC

Important dates

Study start: 2024
Primary completion: 2026
Study completion: 2026
First posted: Jan 30, 2025
Registry last updated: Jan 30, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Active, Not Recruiting